Loading…
Estrella Immunopharma, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -95.2% over 5Y.
today you would have $48.59▼ -95.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $1.56 | $1.20 | $1.11 | $10.29 | $9.91 | |
| P/B | — | — | 10.2x | — | — | — |
| EPS | -$0.35 | -$0.27 | -$36.35 | — | -$0.21 | |
| ROE | — | — | -171.09% | — | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| YI111, Inc. | $3.51 | — | — | — | -14.84% | $30.88M |
| TELATELA Bio, Inc. | $0.70 | — | — | — | — | $31.43M |
| MIRAMIRA Pharmaceuticals Inc | $0.75 | — | 3.9x | — | -217.12% | $31.52M |
| SCLXScilex Holding Co | $4.49 | — |
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Company description provided by Yahoo Finance.
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| $31.59M |
| NNVCNanoviricides Inc | $1.24 | — | 2.9x | — | -89.97% | $31.65M |
| ATNMActinium Pharmaceuticals, Inc. | $1.01 | 2.9x | 1.0x | — | 45.86% | $31.69M |